Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
June 05, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
June 05, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
June 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
RCUS
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
June 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
May 26, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conference
May 25, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
May 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Appoints Cindy Perettie Executive Vice President of Kite
May 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
May 09, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
May 04, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
May 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces First Quarter 2023 Financial Results
April 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
April 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
April 13, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
March 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
March 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
March 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
NRIX
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
February 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite Completes Acquisition of Tmunity
February 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
February 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
February 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
February 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
February 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
February 09, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
February 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
February 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
February 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
January 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
January 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.